☆ 4.7 Article

BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype

SCIENCE IMMUNOLOGY (2021)

Related references

Note: Only part of the references are listed.

Review Virology

Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis

Sahar Sotoodeh Ghorbani et al.

Summary: Studies have shown cases of COVID-19 patients testing positive for the virus again after recovery, with higher reinfection rates in males and more frequent recurrence in females. Uncertainty regarding long-term immunity after SARS-Cov-2 infection indicates the possibility of reinfection and recurrence post-recovery. Efforts like mass vaccination and proper disease management can help control the frequent occurrence of the disease.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Lauren B. Rodda et al.

Summary: The study found that individuals recovered from mild COVID-19 develop sustained SARS-CoV-2-specific immunological memory for at least 3 months, including immunoglobulin antibodies, neutralizing plasma, and memory B and T cells. These memory lymphocytes exhibit potent antiviral function, aiding in immune defense.

CELL (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof et al.

Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Einav G. Levin et al.

Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

Nina Le Bert et al.

Summary: The efficacy of virus-specific T cells in clearing pathogens involves a delicate balance between antiviral and inflammatory responses. Asymptomatic individuals clearing SARS-CoV-2 showed increased production of IFN-gamma and IL-2, along with a proportional secretion of IL-10 and proinflammatory cytokines, while symptomatic individuals displayed a disproportionate secretion of inflammatory cytokines triggered by SARS-CoV-2-specific T cell activation.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Add to Collection

Article Immunology

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Jianmin Zuo et al.

Summary: The study shows that functional SARS-CoV-2-specific T cell responses are retained and robust at 6 months following infection, with higher T cell responses observed in donors who had experienced symptomatic infection. Levels of nucleoprotein-specific T cells were correlated with nucleoprotein-specific antibody levels, providing insights into the persistence and correlation of immune responses.

NATURE IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Rishi R. Goel et al.

Summary: This study found that immune memory to SARS-CoV-2 and its variants remains robust for at least 6 months after mRNA vaccination, with antibodies declining but still detectable in most individuals. mRNA vaccines also induced functional memory B cells and antigen-specific T cells, with recall responses primarily increasing antibody levels in individuals with preexisting immunity.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Adam K. Wheatley et al.

Summary: The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Antibody, B cell, and T cell responses decline over the first 4 months post-infection, while S-specific IgG(+) memory B cells consistently accumulate. The study suggests that natural infection may only provide transient protection at a population level, highlighting the need for more immunogenic and durable vaccines.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Immunology

Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Chang Kyung Kang et al.

Summary: The memory T-cell response to SARS-CoV-2 persists for up to 8 months post-symptom onset, with potentially stronger responses in patients with severe illness compared to those with mild or asymptomatic disease. Further investigations are necessary to assess the longevity and protective effect of this immune response against reinfection.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Victoria Jane Hall et al.

Summary: This study investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. It found that individuals with a previous history of SARS-CoV-2 infection had an 84% lower risk of reinfection, with a median protective effect lasting for 7 months following primary infection.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Article Clinical Neurology

COVID-19 in ocrelizumab-treated people with multiple sclerosis

Richard Hughes et al.

Summary: Limited data on the impact of COVID-19 on people with MS, especially those treated with ocrelizumab, show that most cases are mild and there is no clear association between ocrelizumab exposure duration and COVID-19 severity.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Immunology

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination

Rishi R. Goel et al.

Summary: mRNA vaccines exhibit robust serological and cellular priming, with naïve individuals requiring two doses for optimal antibody responses, especially against the B.1.351 variant. Memory B cells specific for spike protein and RBD were efficiently primed by vaccination, while recovered individuals showed significant boosting after the first dose, correlating with preexisting memory B cell levels. Identifying distinct responses based on prior SARS-CoV-2 exposure suggests that recovered subjects may only need one vaccine dose for peak responses, which can inform vaccine distribution strategies in resource-limited settings.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

Mark M. Painter et al.

Summary: The study found that after SARS-CoV-2 mRNA vaccination, CD4(+) T cell responses in naïve individuals were fast, while CD8(+) T cell responses developed gradually. Th1 and Tfh cell responses after the first dose were correlated with post-boost CD8(+) T cells and neutralizing antibodies.

IMMUNITY (2021)

Add to Collection

Article Multidisciplinary Sciences

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Dami A. Collier et al.

Summary: Elderly individuals, especially those above eighty, show lower immune responses and neutralization abilities against variants of concern after the first vaccine dose, but this improves after the second dose. They have higher frequencies of spike-specific memory B cells but reduced somatic hypermutation of class-switched cells. Production of interferon-gamma and interleukin-2 by SARS-CoV-2 spike-specific T cells is lower in older participants, predominantly by CD4 T cells.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

Prabhu S. Arunachalam et al.

Summary: The study found that vaccination with the Pfizer-BioNTech mRNA vaccine can induce immune responses against neutralizing antibodies and CD4, CD8 T cells of SARS-CoV-2. Booster vaccines can significantly enhance innate immune responses, and different innate pathways associated with CD8 T cells and neutralizing antibodies have been identified.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Jackson S. Turner et al.

Summary: SARS-CoV-2 mRNA vaccines induce a persistent germinal centre B cell response in humans, leading to the generation of robust humoral immunity, especially more significant in individuals previously infected with the virus.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Jianying Liu et al.

Summary: Serum samples from individuals vaccinated with the BNT162b2 vaccine can neutralize various SARS-CoV-2 variants, indicating mass immunization as a central strategy to end the global COVID-19 pandemic.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine

Valerie Oberhardt et al.

Summary: After vaccination, CD8(+) T cells become important effector cells in providing early protection, being effectively mobilized one week after primary vaccination and maintaining stability after booster vaccination. Compared with natural infection, vaccine-induced CD8(+) T cells exhibit similar functional capacities but with a different subset distribution.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Ugur Sahin et al.

Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Talia Kustin et al.

Summary: Breakthrough SARS-CoV-2 infections post-vaccination may be caused by B.1.1.7 or B.1.351 variants, indicating the importance of robust vaccination. Reduced vaccine effectiveness against these variants was observed in the study, highlighting the need for continued surveillance and enhanced vaccination efforts.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Moriah Bergwerk et al.

Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination

Lucie Loyal et al.

Summary: The study demonstrates that preexisting spike-cross-reactive T cells play a functional role in the immune response to SARS-CoV-2 infection and vaccination. Cross-reactive immunity may explain the rapid induction of immunity after primary SARS-CoV-2 immunization and the high rate of asymptomatic or mild COVID-19 cases.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

Jose Mateus et al.

Summary: This study examined the immune responses to the Moderna mRNA-1273 vaccine over 7 months, finding that subjects with preexisting cross-reactive T cell memory exhibited stronger CD4(+) T cell and antibody responses to the vaccine. This demonstrates the biological relevance and potential importance of cross-reactive T cells in generating immunity to SARS-CoV-2.

SCIENCE (2021)

Add to Collection

Article Immunology

Case Report: Sars-CoV-2 Infection in a Vaccinated Individual: Evaluation of the Immunological Profile and Virus Transmission Risk

Claudia Strafella et al.

Summary: Vaccines have shown high efficacy in preventing COVID19 disease, accelerating recovery from infection, and reducing transmission risk. However, factors such as immunological protection, immune response duration, and transmission risk among vaccinated individuals are still under active investigation. A case study of a vaccinated individual infected with a Sars-CoV-2 variant provides valuable insights into infection trajectory and various responses.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis

Klara Asplund Hogelin et al.

Summary: Research showed that almost all seropositive patients and 17.9% of seronegative patients on B cell depleting therapies developed anti-SARS-CoV-2 T cell memory, with functional similarity to controls. Following vaccination, vaccine-specific humoral memory was impaired, but all patients developed a specific T cell response.

ISCIENCE (2021)

Add to Collection

Article Cell Biology

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

Alison Tarke et al.

Summary: The study showed that SARS-CoV-2 variants do not significantly disrupt total T cell reactivity, although decreases in response frequency of 10%-22% were observed under certain assay/VOC combinations. This underscores the importance of actively monitoring T cell responses in the context of SARS-CoV-2 evolution.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset

Shirin Kalimuddin et al.

Summary: The study showed that spike-specific T cells and binding antibodies were detectable 10 days after the first dose of the Pfizer/Bio-NTech BNT162b2 vaccine, suggesting that early T cell and binding antibody responses may induce early protection against COVID-19 compared to receptor blocking or virus neutralizing activity.

MED (2021)

Add to Collection

Article Medicine, Research & Experimental

SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63

Bezawit A. Woldemeskel et al.

Summary: Recent studies have shown that T cells can cross-recognize spike proteins of SARS-CoV-2 and common cold coronaviruses. Vaccination with SARS-CoV-2 mRNA vaccines results in broad T cell responses to the virus's spike protein, including potential recognition of variant spike proteins. Additionally, post-vaccination, there is an observed increase in CD4(+) T cell responses to certain common cold coronaviruses.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Immunology

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost in healthy UK adults

Morven Wilkie et al.

VACCINE (2020)

Add to Collection

Article Immunology

T-cells producing multiple combinations of IFNγ, TNF and IL10 are associated with mild forms of dengue infection

Marcela Helena Goncalves Pereira et al.

IMMUNOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

Add to Collection

Article Immunology

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Ling Ni et al.

IMMUNITY (2020)

Add to Collection

Review Endocrinology & Metabolism

Impact of sex and gender on COVID-19 outcomes in Europe

Catherine Gebhard et al.

BIOLOGY OF SEX DIFFERENCES (2020)

Add to Collection

Letter Biochemistry & Molecular Biology

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

Irani Thevarajan et al.

NATURE MEDICINE (2020)

Add to Collection

Letter Clinical Neurology

Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain

Paloma Montero-Escribano et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Immunology

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Daniela Weiskopf et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Takuya Sekine et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

Naoki Kaneko et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Carolyn Rydyznski Moderbacher et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Julian Braun et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Nina Le Bert et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Jose Mateus et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

A dynamic COVID-19 immune signature includes associations with poor prognosis

Adam G. Laing et al.

NATURE MEDICINE (2020)

Add to Collection

Review Multidisciplinary Sciences

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Angkana T. Huang et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Immunology

Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19

Petra Bacher et al.

IMMUNITY (2020)

Add to Collection

Article Immunology

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Katlyn Lederer et al.

IMMUNITY (2020)

Add to Collection

Article Immunology

Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

Catherine J. Reynolds et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

Anthony L. Cunningham et al.

JOURNAL OF INFECTIOUS DISEASES (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Human TSCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness

Pedro Costa del Amo et al.

PLOS BIOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Origin and differentiation of human memory CD8 T cells after vaccination

Rama S. Akondy et al.

NATURE (2017)

Add to Collection

Review Biochemistry & Molecular Biology

T memory stem cells in health and disease

Luca Gattinoni et al.

NATURE MEDICINE (2017)

Add to Collection

Article Multidisciplinary Sciences

Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells

Samantha Reiss et al.

PLOS ONE (2017)

Add to Collection

Review Pharmacology & Pharmacy

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV

William J. Liu et al.

ANTIVIRAL RESEARCH (2017)

Add to Collection

Review Immunology

Sex differences in immune responses

Sabra L. Klein et al.

NATURE REVIEWS IMMUNOLOGY (2016)

Add to Collection

Article Immunology

A brief history of T cell help to B cells

Shane Crotty

NATURE REVIEWS IMMUNOLOGY (2015)

Add to Collection

Article Immunology

Circulating CXCR5+PD-1+ Response Predicts Influenza Vaccine Antibody Responses in Young Adults but not Elderly Adults

Ramin Sedaghat Herati et al.

JOURNAL OF IMMUNOLOGY (2014)

Add to Collection

Article Immunology

Preexisting High Frequencies of Memory CD8+ T Cells Favor Rapid Memory Differentiation and Preservation of Proliferative Potential upon Boosting

Kathryn A. Fraser et al.

IMMUNITY (2013)

Add to Collection

Article Biochemistry & Molecular Biology

Cellular immune correlates of protection against symptomatic pandemic influenza

Saranya Sridhar et al.

NATURE MEDICINE (2013)

Add to Collection

Article Cell Biology

Induction of ICOS+CXCR3+CXCR5+ TH Cells Correlates with Antibody Responses to Influenza Vaccination

Salah-Eddine Bentebibel et al.

SCIENCE TRANSLATIONAL MEDICINE (2013)

Add to Collection

Article Biochemical Research Methods

SPICE: Exploration and Analysis of Post-Cytometric Complex Multivariate Datasets

Mario Roederer et al.

CYTOMETRY PART A (2011)

Add to Collection

Article Biochemistry & Molecular Biology

A human memory T cell subset with stem cell-like properties

Luca Gattinoni et al.

NATURE MEDICINE (2011)

Add to Collection

Article Immunology

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

Troy D. Querec et al.

NATURE IMMUNOLOGY (2009)

Add to Collection

Article Immunology

Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines

Joseph D. Miller et al.

IMMUNITY (2008)

Add to Collection

Article Immunology

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

Denis Gaucher et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2008)

Add to Collection

Article Biochemistry & Molecular Biology

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

Patricia A. Darrah et al.

NATURE MEDICINE (2007)

Add to Collection

Article Immunology

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses

Melissa L. Precopio et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.